Quantitative activity-activity relationship (QAAR) driven design to develop hydroxamate derivatives of pentanoic acids as selective HDAC8 inhibitors: synthesis, biological evaluation and binding mode of interaction studies

被引:12
作者
Amin, Sk Abdul [1 ]
Trivedi, Prakruti [2 ]
Adhikari, Nilanjan [1 ]
Routholla, Ganesh [2 ]
Vijayasarathi, Dhanya [2 ]
Das, Sanjib [1 ]
Ghosh, Balaram [2 ]
Jha, Tarun [1 ]
机构
[1] Jadavpur Univ, Dept Pharmaceut Technol, Div Med & Pharmaceut Chem, Nat Sci Lab, Kolkata 700032, India
[2] BITS Pilani, Epigenet Res Lab, Dept Pharm, Hyderabad Campus, Hyderabad 500078, India
关键词
HISTONE DEACETYLASE INHIBITORS; IN-SILICO; MOLECULAR DOCKING; DISEASE;
D O I
10.1039/d1nj02636d
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Histone deacetylase 8 (HDAC8) has been implicated as a potential drug target of many diseases including cancer. HDAC8 isoform selectivity over other class-I HDACs is a major concern nowadays. In this work, a series of pentanoic acid based hydroxamates with different substituted cap groups have been designed, synthesized, characterized, and screened against class-I HDACs. A quantitative activity-activity relationship (QAAR) model was developed to design HDAC8 selective inhibitors. The designed compounds obtained through the molecular modeling study were synthesized, characterized, and their enzymatic as well as cytotoxic activities were measured. Two compounds 7i and 7f are found to be selective HDAC8 inhibitors over other class-I HDACs. These compounds possess better antiproliferative activities against some cancer cell lines. These observations are in agreement with the molecular docking studies for the binding mode of interactions. Further studies show that compounds 7i and 7f induce significant cell growth arrest in the G2/M phase, indicating their anticancer potentials. In summary, our study confirms pentanoic acid based hydroxamate as selective HDAC8 inhibitors and two compounds 7i and 7f may serve as lead molecules for further investigation.
引用
收藏
页码:17149 / 17162
页数:14
相关论文
共 39 条
[1]   Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays [J].
Adhikari, Nilanjan ;
Halder, Amit K. ;
Mallick, Sumana ;
Saha, Achintya ;
Saha, Kishna D. ;
Jha, Tarun .
BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (18) :4291-4309
[2]   Exploring structural requirements of leads for improving activity and selectivity against CDK5/p25 in Alzheimer's disease: an in silico approach [J].
Ambure, Pravin ;
Roy, Kunal .
RSC ADVANCES, 2014, 4 (13) :6702-6709
[3]   Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity [J].
Amin, Sk Abdul ;
Adhikari, Nilanjan ;
Jha, Tarun .
FUTURE MEDICINAL CHEMISTRY, 2018, 10 (13) :1589-1602
[4]   First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington's disease: A proposal to chemists! [J].
Amin, Sk. Abdul ;
Adhikari, Nilanjan ;
Jha, Tarun ;
Gayen, Shovanlal .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (23) :5712-5718
[5]  
[Anonymous], QSAR TOOLS
[6]  
[Anonymous], 2015, CHEMDRAW ULTR 8 0
[7]   Recent advances in class IIa histone deacetylases research [J].
Asfaha, Yodita ;
Schrenk, Christian ;
Avelar, Leandro A. Alves ;
Hamacher, Alexandra ;
Pflieger, Marc ;
Kassack, Matthias U. ;
Kurz, Thomas .
BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (22)
[8]   Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth [J].
Bergman, Joel A. ;
Woan, Karrune ;
Perez-Villarroel, Patricio ;
Villagra, Alejandro ;
Sotomayor, Eduardo M. ;
Kozikowski, Alan P. .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (22) :9891-9899
[9]   Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD) [J].
Bourguet, Erika ;
Ozdarska, Katarzyna ;
Moroy, Gautier ;
Jeanblanc, Jerome ;
Naassila, Mickael .
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (05) :1745-1766
[10]   HDAC8: a multifaceted target for therapeutic interventions [J].
Chakrabarti, Alokta ;
Oehme, Ina ;
Witt, Olaf ;
Oliveira, Guilherme ;
Sippl, Wolfgang ;
Romier, Christophe ;
Pierce, Raymond J. ;
Jung, Manfred .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (07) :481-492